Insights into SARS-CoV-2 Surveillance among Prison Populations in Mato Grosso do Sul, Brazil, in 2022.

Insights into SARS-CoV-2 Surveillance among Prison Populations in Mato Grosso do Sul, Brazil, in 2022.

Publication date: Jul 16, 2024

This study examines the epidemiological and genomic characteristics, along with the transmission dynamics, of SARS-CoV-2 within prison units I and II in Campo Grande, Mato Grosso do Sul, Brazil. Conducted between May and October 2022, it reveals how the virus spreads in the confined settings of prisons, emphasizing the roles of overcrowded cells, frequent transfers, and limited healthcare access. The research involved 1927 participants (83. 93% of the total prison population) and utilized nasopharyngeal swabs and RT-qPCR testing for detection. Contact tracing monitored exposure within cells. Out of 2108 samples, 66 positive cases were identified (3. 13%), mostly asymptomatic (77. 27%), with the majority aged 21-29 and varying vaccination statuses. Next-generation sequencing generated 28 whole genome sequences, identifying the Omicron variant (subtypes BA. 2 and BA. 5) with 99% average coverage. Additionally, the study seeks to determine the relationship between immunization levels and the incidence of SARS-CoV-2 cases within this enclosed population. The findings underscore the necessity of comprehensive control strategies in prisons, including rigorous screening, isolation protocols, vaccination, epidemiological monitoring, and genomic surveillance to mitigate disease transmission and protect both the incarcerated population and the broader community.

Open Access PDF

Concepts Keywords
Genome Adolescent
Healthcare Adult
Overcrowded Aged
Prisons Brazil
Contact Tracing
COVID-19
COVID-19
Epidemiological Monitoring
epidemiological monitoring
Female
Genome, Viral
genomic monitoring
Humans
Male
Middle Aged
Phylogeny
prison
Prisoners
Prisons
SARS-CoV-2
SARS-CoV-2
Whole Genome Sequencing
Young Adult

Semantics

Type Source Name
disease VO population
disease IDO contact tracing
disease VO vaccination
disease VO immunization
drug DRUGBANK Coenzyme M
drug DRUGBANK Efavirenz
drug DRUGBANK Ribostamycin
drug DRUGBANK L-Phenylalanine
disease VO USA
disease MESH COVID 19
disease VO organization
disease MESH causes
disease MESH infections
disease MESH infectious diseases
disease VO Gap
disease MESH emergency
disease IDO country
disease VO effective
drug DRUGBANK Etoperidone
disease IDO process
disease VO storage
disease VO CoronaVac
disease VO vaccine
disease VO protocol
disease VO manufacturer
disease VO time
disease IDO assay
disease IDO infection
disease VO unvaccinated
disease VO vaccine efficacy
disease VO dose
drug DRUGBANK Aspartame
disease IDO susceptibility
disease VO vaccine dose
disease VO frequency
disease VO effectiveness
disease IDO susceptible population
disease IDO host
disease MESH asymptomatic infections
disease VO vaccination protocol
disease IDO symptom
disease MESH sore throat
disease IDO cell
disease IDO facility
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease IDO drug susceptibility
disease VO efficient
drug DRUGBANK Pentaerythritol tetranitrate

Original Article

(Visited 2 times, 1 visits today)